[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
3. Oguri T, Achiwa H, Kato D, Maeda H, Niimi T, Sato S, Ueda R: Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy; 2004 Dec;50(6):279-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma.
  • Thymic carcinoma is a rare and aggressive tumor, and the efficacy of second-line chemotherapy is still unclear.
  • Here, we reported a case of thymic carcinoma that responded well to the administration of docetaxel alone as a second-line chemotherapy.
  • A 64-year-old woman was diagnosed with thymic carcinoma (squamous cell type) with bone metastasis, and she, therefore, received nedaplatin combined with etoposide and ifosfamide.
  • Two months after chemotherapy, the thymic carcinoma exhibited gradual regrowth and she experienced shoulder pain.
  • This case demonstrated that docetaxel is effective as a second-line chemotherapy for thymic carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Cervical Vertebrae / pathology. Mediastinal Neoplasms / drug therapy. Salvage Therapy / methods. Spinal Neoplasms / drug therapy. Taxoids / therapeutic use. Thymoma / drug therapy. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Female. Humans. Mediastinum / radiography. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15608443.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


Advertisement
4. Tanaka A, Osawa H, Yamauchi A, Asahina H, Kikuchi H, Ogura S, Yamamoto K, Ikeda H, Koshiba R: [Clinical study of eight thymic carcinomas]. Kyobu Geka; 2002 Oct;55(11):971-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of eight thymic carcinomas].
  • Eight patients with thymic carcinoma were surgically treated at Sapporo City General Hospital from September 1990 to January 2002.
  • The histological subtypes of thymic carcinoma were squamous cell in 5, undifferentiated in 2, and small cell in one.
  • Of 3 cases with intra pericardial malignant effusion, one patient survived 7 years without recurrence of the tumor after the exploratory operation followed by mediastinal irradiation without chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Thymoma / surgery. Thymus Neoplasms / surgery
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12391695.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; ADOC protocol
  •  go-up   go-down


5. Yang JT, Chang CM, Lee MH, Chen YJ, Lee KF: Thymic squamous cell carcinoma with multiple brain metastases. Acta Neurol Taiwan; 2010 Mar;19(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic squamous cell carcinoma with multiple brain metastases.
  • Thymic carcinomas are rare epithelial malignancies with marked invasive tendency which can metastasize to distant organs, most commonly to the lung, bone, liver, kidney and extra-thoracic lymph nodes.
  • We reported a 42-year-old male with thymic squamous cell carcinoma and lung and bones metastases.
  • Based on the clinical symptoms of severe headache and vomiting and the results of brain computed tomography and magnetic resonance imaging scans, 2 metastatic tumors with a cystic component were diagnosed.
  • The patient underwent continuous chemotherapy systemically and whole brain irradiation for disease control.
  • This presentation suggests that surgical resection with concurrent chemo-radiotherapy is the treatment of choice for thymic carcinomas with brain metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Thymoma / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714951.001).
  • [ISSN] 1028-768X
  • [Journal-full-title] Acta neurologica Taiwanica
  • [ISO-abbreviation] Acta Neurol Taiwan
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


6. Kuriyama S, Ohashi R, Matsuda K, Sugano K, Muraki K, Minakata K, Ishiwata T, Hirama M, Kodama Y, Oh S, Suzuki K, Takahashi K: [Twelve cases of advanced thymic carcinoma: a clinical review]. Nihon Kokyuki Gakkai Zasshi; 2010 Aug;48(8):604-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Twelve cases of advanced thymic carcinoma: a clinical review].
  • Thymic carcinoma is comparatively rare and no standard treatment has been established for advanced stage cases.
  • We reviewed our therapeutic experience in 12 cases of thymic carcinoma.
  • Nine cases were squamous cell carcinoma and 3 were adenocarcinoma.
  • Chemotherapy combined with radiation therapy was given in 1 case, chemotherapy (monotherapy) was given in 4 cases, radiation therapy was given in 1 case, and 2 cases received best supportive care.
  • The median survival time (MST) of patients who had undergone combined modality treatments including surgery was 1971 days, which was longer than the MST of 567 days of patients who were not able to undergo surgery.
  • The prognosis outcome of advanced thymic carcinoma is poor, but combined modality therapies such as surgery, chemotherapy and radiation can be effective for some advanced thymic carcinoma cases.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Squamous Cell / therapy. Thymus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20803979.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Okada M, Koizumi T, Yasuo M, Tsushima K, Urushihata K, Yamaguchi S, Hanaoka M, Fujimoto K, Kubo K: [Successful treatment of intrapericardial administration of carboplatin following systemic chemotherapy in a case of advanced thymic cancer with cardiac tamponade]. Nihon Kokyuki Gakkai Zasshi; 2006 Dec;44(12):968-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of intrapericardial administration of carboplatin following systemic chemotherapy in a case of advanced thymic cancer with cardiac tamponade].
  • A 72-year-old woman developed cardiac tamponade due to direct invasion of thymic cancer.
  • Carboplatin was administered into the pericardial cavity two times with a total dose of 600 mg.
  • Following four cycles of systemic chemotherapy by carboplatin, doxorubicin, vincristine, cyclophosphamide (ADOC), partial response was obtained.
  • Intrapericardial administration of carboplatin is a useful therapy for control of pericardial effusion and chemosensitive cases should de identified among patients with thymic cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cardiac Tamponade / drug therapy. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Liver Neoplasms / secondary. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / etiology. Remission Induction. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233396.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; ADOC protocol
  •  go-up   go-down


8. Ogawa K, Toita T, Uno T, Fuwa N, Kakinohana Y, Kamata M, Koja K, Kinjo T, Adachi G, Murayama S: Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer; 2002 Jun 15;94(12):3115-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases.
  • BACKGROUND: Thymic carcinomas are rare neoplasms, and information regarding the results of treatment and possible prognostic factors in patients with these tumors is limited.
  • METHODS: The records of 40 patients with histologically confirmed thymic carcinoma who were treated between 1984 and 1998 were reviewed.
  • Twenty-seven patients were treated with surgical resection followed by radiotherapy with or without chemotherapy, and the remaining 13 patients were treated with radiotherapy with or without chemotherapy.
  • The median follow-up time for the 13 surviving patients was 87 months (range, 44-193 months).
  • On univariate analysis, complete resection, Karnofsky performance status (KPS), histology, and Masaoka stage at the time of diagnosis were found to have a significant impact on overall survival, whereas on multivariate analysis, complete resection, KPS, and histology were found to be significant prognostic factors.
  • With regard to the degree of resection, 12 of 16 patients (75%) treated with complete resection were alive and free of disease at the time of last follow-up whereas 1 of 24 patients (4%) treated with incomplete resection or biopsy still was alive.
  • Among 12 surviving patients treated with complete resection, 8 with resectable tumors at the time of presentation all had low-grade histology (squamous cell carcinoma) and were treated successfully with complete resection and postoperative radiotherapy with or without adjuvant chemotherapy.
  • The remaining four patients with unresectable tumors at the time of presentation were treated successfully with neoadjuvant chemotherapy, complete resection, and postoperative radiotherapy.
  • CONCLUSIONS: The results of the current study indicate that multimodal treatment, especially complete resection and postoperative radiotherapy with or without chemotherapy, is a curative therapy for thymic carcinomas.
  • [MeSH-major] Thymus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12115342.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Nagai K, Nagahiro I, Aoe M, Yamashita M, Okabe K, Date H, Ando A, Shimizu N: [Two cases of thymic carcinoma effectively treated by preoperative chemotherapy]. Kyobu Geka; 2000 May;53(5):421-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of thymic carcinoma effectively treated by preoperative chemotherapy].
  • Percutaneous needle biopsy yielded a diagnosis of epitherial carcinoma.
  • The patient underwent 3 courses of systemic chemotherapy (CDDP + ADM + VCR + CPA).
  • Examination of the resected tumor revealed partial response to chemotherapy.
  • Percutaneous needle biopsy yielded a diagnosis of squamous cell carcinoma of thymus.
  • The patient underwent 3 courses of systemic chemotherapy.
  • Examination of the resected tumor revealed partial response to chemotherapy.
  • These cases indicate the usefulness of preoperative chemotherapy for advanced thymic carcinoma to reduce tumor size and to control local invasion, distant metastasis before operation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclosporine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Preoperative Care. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10808295.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Tsurusaki M, Mimura F, Sugihara R, Okada M: [A case of advanced thymic cancer successfully treated with neoadjuvant intra-arterial infusion chemotherapy]. Gan To Kagaku Ryoho; 2003 Nov;30(12):1959-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced thymic cancer successfully treated with neoadjuvant intra-arterial infusion chemotherapy].
  • We report the case of a 68-year-old man with advanced thymic cancer who was diagnosed as having squamous cell carcinoma by percutaneous needle biopsy.
  • Induction systemic chemotherapy consisting of CDDP (70 mg/m2, day 1), ADM (40 mg/m2, day 1) and ETP (70 mg/m2, day 1-3) was performed for the purpose of reducing the tumor size; however, the tumor's size did not shrink.
  • Therefore, second line chemotherapy combined with selective intra-arterial infusion chemotherapy and systemic chemotherapy consisting of CDDP (70 mg/m2, day 1; intra-arterial), ADM (30 mg/m2, day 1; intra-arterial), VCR (0.5 mg/m2, day 3; systemic) and CPA (500 mg/m2, day 3; systemic) was performed.
  • After this treatment, the tumor was reduced in size, and an extended thymectomy was subsequently performed.
  • The histological diagnosis of the resected tumor was squamous cell carcinoma.
  • These results show that intra-arterial infusion chemotherapy may be effective for local control of advanced thymic cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Thymectomy. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Male. Neoadjuvant Therapy. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650967.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. D'Angelillo RM, Trodella L, Ramella S, Cellini N, Balducci M, Mantini G, Cellini F, Ciresa M, Fiore M, Evoli A, Sterzi S, Russo P, Grozio A, Cesario A, Granone P: Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. Int J Radiat Oncol Biol Phys; 2008 Jun 1;71(2):420-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection.
  • PURPOSE: To assess the role of multimodality treatment on patients with thymic epithelial tumors (TETs) (i.e., thymomas and thymic squamous cell carcinoma) and to define the prognostic classes according to the Masaoka and World Health Organization histologic classification systems.
  • METHODS AND MATERIALS: Primary surgery was the mainstay of therapy.
  • Adjuvant chemotherapy was administered in selected cases.
  • CONCLUSION: The analysis of our experience singled out three novel prognostic classes and the assessment of risk identified treatment selection criteria.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Thymoma / therapy. Thymus Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Esophagus / radiation effects. Female. Humans. Lung / radiation effects. Male. Middle Aged. Myasthenia Gravis / epidemiology. Neoplasm Recurrence, Local. Prognosis. Radiation Injuries / pathology. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Survival Analysis. World Health Organization

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164843.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Maruyama R, Suemitsu R, Okamoto T, Kojo M, Aoki Y, Wataya H, Eguchi T, Nishiyama K, Seto T, Ichinose Y: Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients. Oncology; 2006;70(5):325-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients.
  • OBJECTIVES: The aim of this study is to retrospectively evaluate the role of several therapies, mainly chemotherapy, for thymic carcinoma (TC).
  • The histological subtype was in all cases squamous cell carcinoma, nonkeratinizing type.
  • RESULTS: There were 6 complete surgical resections, 1 incomplete resection followed by chemoradiotherapy, 6 with radiotherapy alone, 3 with radiotherapy plus chemotherapy, and 9 with chemotherapy alone as the initial treatment.
  • Eighteen patients were administered second-line therapy.
  • The regimen obtaining the best response rate was doublet chemotherapy consisting of carboplatin (CBDCA) and paclitaxel.
  • The median survival time and survival rate at 5 years for the patients excluding surgical cases with stage I/II disease were 32 months and 31%, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Thymoma / therapy. Thymus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17164588.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Matsuoka T, Kobayashi S, Oka K, Sakano H, Kawano K, Katoh T: [Thymic cancer with superior vena cava invasion reconstructed by ready-made Y-graft]. Kyobu Geka; 2010 May;63(5):379-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thymic cancer with superior vena cava invasion reconstructed by ready-made Y-graft].
  • Computed tomography (CT) showed the lobulated tumor suspected of superior vena cava (SVC) invasion, located in the anterior mediastinum, 5 x 3 cm in size.
  • Histopathological diagnosis was thymic cancer, poorly differentiated squamous cell carcinoma.
  • Postoperative radiotherapy (RT : 12.6 Gy) was canceled for the side effect.
  • Alternatively, adjuvant chemotherapy [carboplatin (CBDCA) +paclitaxel (PTX)] was administered.
  • Additional RT (50 Gy) was given to the lesion of local recurrence 1 and half year after the operation.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Neoplasm Invasiveness / pathology. Thymus Neoplasms / pathology. Vena Cava, Superior / pathology. Vena Cava, Superior / surgery

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446606.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Yano M, Sasaki H, Yokoyama T, Yukiue H, Kawano O, Okuda K, Fujii Y: Thymic carcinoma with dissemination: a retrospective analysis of ten patients. Gen Thorac Cardiovasc Surg; 2008 Jul;56(7):335-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic carcinoma with dissemination: a retrospective analysis of ten patients.
  • OBJECTIVE: Thymic carcinoma is a rare mediastinal neoplasm with frequent pleural or pericardial dissemination.
  • METHODS: Ten thymic carcinoma patients with dissemination have been treated since 1987.
  • RESULTS: Pretreatment tumor biopsy was performed and demonstrated squamous cell carcinomas in nine and small cell carcinoma in one.
  • These patients were basically regarded as inoperable and treated with chemotherapy and/or radiotherapy.
  • Four other patients were diagnosed as cT3 preoperatively but were found to have dissemination at the time of thoracotomy.
  • They underwent total resection of the thymic tumor and all visible pleural dissemination but without pericardial dissemination.
  • Radiotherapy was performed pre-or postoperatively with or without chemotherapy.
  • CONCLUSIONS: Among thymic carcinoma patients with pleural or pericardial dissemination, there seem to be some patients who show good prognosis.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Pericardium / pathology. Pleura / pathology. Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Thoracotomy. Thymectomy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Sci. 2005 Oct;330(4):172-5 [16234609.001]
  • [Cites] Ann Thorac Surg. 2003 Sep;76(3):878-84; discussion 884-5 [12963221.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):1025-32 [1991250.001]
  • [Cites] Ann Thorac Surg. 2003 Oct;76(4):1041-5 [14529981.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3115-9 [12115342.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2485-92 [7296496.001]
  • (PMID = 18607680.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Mochizuki T, Numata T, Kimura A, Onodera R, Kojima A, Kotajima F, Satou T, Tai H, Satou S, Akiba N, Yosimura K, Ito H, Oka T: [Thymic carcinoma. A clinicopathological study of seven patients]. Nihon Kokyuki Gakkai Zasshi; 2004 Jul;42(7):634-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thymic carcinoma. A clinicopathological study of seven patients].
  • The treatment of seven cases of thymic carcinoma is reported.
  • Five were identified histopathologically as squamous cell carcinoma, one as undifferentiated carcinoma, and one as small cell neuroendocrine carcinoma.
  • Surgery was performed during the course of chemotherapy and radiotherapy in 5 cases, and in 2, the organs infiltrated by neoplastic cells were partially excised together.
  • Radiotherapy was performed as adjuvant therapy in one case of partial excision.
  • In another case, after six years of chemotherapy and radiotherapy that yielded a partial response (PR), cancerous infiltration of the chest wall occurred, and partial removal of the chest wall became necessary.
  • After the remaining case showed a PR to chemotherapy, complete macroscopic excision of the tumor was undertaken, but mediastinal lymph gland metastasis was present, and so radiotherapy was also initiated.
  • One of these was treated with chemotherapy alone, the other, only with radiotherapy.
  • One of the two who survived for over four years had squamous cell carcinoma, the other, undifferentiated carcinoma.
  • The case of small cell neuroendocrine carcinoma was assessed as having a PR, and so complete extraction of the thymic neoplasm was carried out, and followed with radiotherapy.
  • [MeSH-major] Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15357265.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Kondo K, Monden Y: [Thymic carcinoma]. Kyobu Geka; 2002 Jul;55(8 Suppl):701-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thymic carcinoma].
  • Thymic epithelial tumors are mainly consisted of thymoma, thymic carcinoma, and thymic carcinoid.
  • And thymic carcinoma is very rare neoplasm.
  • The classification of thymic carcinoma has remained a subject of controversy for many years.
  • The outline of thymic carcinoma has been clarified by "Atlas of Tumor Pathology: Tumors of the Mediastium (AFIP)" and "Histrogical Typing of Tumours of the Thymus (WHO)" published recently.
  • Squamous cell carcinoma is by far the most common in Japan.
  • Thymic carcinoma is a predilection for male.
  • Thymic carcinoma already had contiguous invasion around neighbor organs, dissemination, and lymph node metastases or distant metastases at diagnosis.
  • Two third of patients with thymic carcinoma performed surgery, and most of them performed adjuvant radiotherapy or chemotherapy.
  • 5-year survival of thymic carcinoma was 33-50%.
  • Histologic tumor type, type of tumor margin, growth pattern, nuclear atypia, necrosis and mitotic activity were correlated with survival.
  • In this paper thymic carcinoma is reviewed mainly based on recently literatures and results obtained from a questionnaire on thymic epithelial tumors in Japan.
  • [MeSH-major] Thymoma. Thymus Neoplasms

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174662.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 29
  •  go-up   go-down


17. Koizumi T, Takabayashi Y, Yamagishi S, Tsushima K, Takamizawa A, Tsukadaira A, Yamamoto H, Yamazaki Y, Yamaguchi S, Fujimoto K, Kubo K, Hirose Y, Hirayama J, Saegusa H: Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol; 2002 Jun;25(3):266-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy).
  • The role of systemic chemotherapy and optimal regimen in thymic carcinoma remains uncertain.
  • We evaluated the clinical responsiveness of ADOC (cisplatin, doxorubicin, vincristine, and cyclophosphamide) chemotherapy for advanced thymic carcinoma that have distant metastatic or unresectable lesions.
  • From 1996 to 2000, we treated eight cases of thymic carcinoma.
  • Histologic subtypes were as follows: four cases were squamous cell carcinoma, two cases were undifferentiated, and two were small-cell carcinoma.
  • Six patients obtained a partial response after ADOC chemotherapy and the overall clinical response rate was 75%.
  • Cisplatin plus VP-16 chemotherapy (PVP) was performed in three cases before the ADOC regimen, but PVP chemotherapy did not show beneficial effects in two patients.
  • Median survival time was 19 months.
  • ADOC chemotherapy appears to have significant activity against thymic carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma / drug therapy. Carcinoma / pathology. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12040285.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; ADOC protocol
  •  go-up   go-down


18. Cheng MF, Tsai CS, Chiang PC, Lee HS: Cardiac tamponade as manifestation of advanced thymic carcinoma. Heart Lung; 2005 Mar-Apr;34(2):136-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade as manifestation of advanced thymic carcinoma.
  • Thymic carcinoma, a malignant thymoma, is rare in the anterior mediastinum.
  • Typically it occurs after age 40 years, presents as an asymptomatic disorder for prolonged periods of time, and is incidentally detected by chest radiograph.
  • We now report the case of a 47-year-old man who experienced sudden onset syncope because of cardiac tamponade and massive pleural and pericardial effusions resulting from a huge thymic tumor.
  • Pathologic examination showed a moderately differentiated squamous cell carcinoma.
  • Postoperative radiotherapy and chemotherapy were introduced.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Cardiac Tamponade / etiology. Thymus Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Echocardiography. Electrocardiography. Female. Fluorouracil. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Middle Aged. Pericardial Effusion / etiology. Pericardial Effusion / surgery. Pericardial Effusion / ultrasonography. Pericardiocentesis. Postoperative Care. Radiography, Thoracic. Radiotherapy Dosage. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761459.001).
  • [ISSN] 0147-9563
  • [Journal-full-title] Heart & lung : the journal of critical care
  • [ISO-abbreviation] Heart Lung
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Adachi K, Hosaka N, Takao M, Fujinaga K: [Clinicopathologic study of thymic epithelial tumors]. Kyobu Geka; 2005 Feb;58(2):119-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of thymic epithelial tumors].
  • OBJECTIVE: We analyzed clinicopathologic characters and long-term results of 11 thymic epithelial tumors.
  • METHODS: Five cases of thymic carcinoma and 6 cases of thymoma treated in our hospital from September 1991 to June 2002 were retrospectively analyzed.
  • RESULTS: The histological subtypes of thymic carcinoma were basaloid carcinoma in 2 cases, epidermoid non-keratinizing carcinoma in 1 case, undifferentiated carcinoma in 1 case and sarcomatoid carcinoma in 1 case.
  • Four cases underwent chemotherapy and radiotherapy.
  • Two cases of basaloid carcinoma had been alive more than 10 years since the operation.
  • The histological subtypes of thymoma were 1, 2, 1, 1 and 1 cases with type A, AB, B 1, B 2 and B 3.
  • Strong immunoreactivity for bcl-2 and p 53 expression of epidermoid non-keratinizing carcinoma and undifferentiated carcinoma were seen. ki-67 labeling index of epidermoid non-keratinizing carcinoma and undifferentiated carcinoma and type B 3 thymoma were higher than those of the other carcinomas and thymomas.
  • [MeSH-major] Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma / pathology. Carcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Female. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Retrospective Studies. Thymectomy

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15724473.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


20. Kaira K, Watanabe R, Takise A, Endou K, Kamiyoshihara M, Mori M: [Thymic cancer effectively treated by combination chemotherapy of carboplatin and etoposide with concurrent radiotherapy]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1989-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thymic cancer effectively treated by combination chemotherapy of carboplatin and etoposide with concurrent radiotherapy].
  • Percutaneous needle biopsy showed that the mass was an advanced thymic cancer (squamous cell carcinoma).
  • The patient was treated by combination chemotherapy of carboplatin and etoposide with concurrent radiotherapy (44 Gy).
  • After 3 courses of chemotherapy, the mass showed an approximately 81% reduction in tumor size and disappearance of the pericardial effusion.
  • Finally, the thymic cancer and small pulmonary metastatic lesions were all resected.
  • This concurrent chemoradiotherapy can be effective against inoperable squamous cell carcinoma of the thymus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Thymus Neoplasms / drug therapy. Thymus Neoplasms / radiotherapy
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Middle Aged. Thymectomy

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282742.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


23. Ströbel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Müller-Hermelink HK, Marx A: Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol; 2004 Apr 15;22(8):1501-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis.
  • PURPOSE: Thymic epithelial tumors (TET) are rare epithelial neoplasms of the thymus with considerable histologic heterogeneity.
  • This retrospective study focused on the correlation of WHO-defined TET histotypes with survival and tumor recurrence in a large cohort of patients receiving different modes of treatment.
  • Forty-two patients received adjuvant radiotherapy (mean dose, 53 Gy), and 33 patients received adjuvant chemotherapy.
  • RESULTS: Seventy-six (88%) of 86 patients with WHO type A, AB, and B1 thymomas were treated by surgery alone, with three tumor relapses after 3 to 10 years (median, 3.4 years).
  • Twelve of 67 patients with WHO type B2 and B3 thymomas in Masaoka stages I and II were treated by adjuvant radiotherapy without evidence of tumor recurrence after 1 to 12 years (median, 4 years).
  • CONCLUSION: The long-term outcome of TET patients is related to tumor stage, WHO histotype, completeness of surgical removal, and type of treatment.
  • Prospective trials are warranted to formally address the efficacy of adjuvant therapy in the treatment of localized and advanced malignant TETs.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Neoplasm Recurrence, Local / pathology. Thymoma / pathology. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15084623.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Fukuda M, Obase Y, Miyashita N, Kobashi Y, Mohri K, Ueno S, Hayama M, Shimizu K, Nishimura H, Nakata M, Oka M: Paclitaxel and cisplatin with concurrent radiotherapy followed by surgery in locally advanced thymic carcinoma. Anticancer Res; 2007 May-Jun;27(3B):1601-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and cisplatin with concurrent radiotherapy followed by surgery in locally advanced thymic carcinoma.
  • Thymic carcinoma is a rare neoplasm with a poor prognosis.
  • We report the clinical course of a patient who received complete surgical resection after effective induction treatment.
  • A 72-year-old woman with advanced thymic carcinoma (squamous cell carcinoma, stage IVb) was considered as nonresectable due to invasion of neighboring organs and mediastinal lymph node metastasis.
  • Two cycles of chemotherapy, consisting of paclitaxel (180 mg/m2) plus cisplatin (80 mg/m2), combined with thoracic radiotherapy (total 54 Gy) were performed concurrently and complete radical resection could then be performed.
  • This multimodal treatment may be a good treatment option for locally advanced thymic carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Paclitaxel / therapeutic use. Thymoma / drug therapy. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Radiography, Thoracic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595782.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Abiko M, Satoh T: [Effect of preoperative concurrent chemo-radiotherapy for thymic carcinoma]. Kyobu Geka; 2002 Oct;55(11):965-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of preoperative concurrent chemo-radiotherapy for thymic carcinoma].
  • Ten cases of thymic carcinoma were operated in our hospital from 1975 to 2000.
  • They underwent 2 courses of systemic chemotherapy [cisplatin (CDDP) + etoposide (VP-16)] with concurrent radiotherapy (40 Gy).
  • We had one complete-response, one partial-response and one no-response by the induction therapy.
  • Only the no-responder underwent one more course of chemotherapy [CDDP + gemcitabine (GEM)].
  • Operations were performed four weeks after the end of the induction therapy.
  • Therefore, it was revealed that the induction concurrent chemo-radiotherapy for thymic carcinomas is extremely effective for some patients but invalid for other cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Deoxycytidine / analogs & derivatives. Thymoma / drug therapy. Thymoma / radiotherapy. Thymus Neoplasms / drug therapy. Thymus Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Male. Middle Aged. Preoperative Care. Radiotherapy Dosage. Remission Induction

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12391694.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Takeda S, Sawabata N, Inoue M, Koma M, Maeda H, Hirano H: Thymic carcinoma. Clinical institutional experience with 15 patients. Eur J Cardiothorac Surg; 2004 Aug;26(2):401-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic carcinoma. Clinical institutional experience with 15 patients.
  • OBJECTIVE: We retrospectively evaluated 15 patients with thymic carcinoma treated with various modalities and investigated overall management of this disease.
  • METHODS: From 1983 to 2003, we treated 15 patients with thymic carcinoma (12 squamous cell carcinomas, 2 undifferentiated carcinomas and one adenocarcinoma).
  • RESULTS: Ten patients were histologically diagnosed preoperatively, and 5 patients underwent an exploratory procedure under the diagnosis of thymoma or benign teratoma.
  • Complete resection was performed in 9 patients (2 stage II, 5 stage III and 2 stage IVa), which included 4 patients who received induction therapy, 4 who received postoperative radiation therapy, and 1 who received postoperative chemotherapy.
  • Six patients with unresectable tumors were treated by irradiation (40-60 Gy) with or without chemotherapy.
  • CONCLUSIONS: We concluded that a complete resection is mainstay of therapy when possible, but chemoradiation therapy being potential benefit in the management of thymic carcinoma.
  • However, considering the high prevalence of advanced stage patients, to establish the effective regimen of induction therapy in the additional multicenter trials should be mandatory.
  • [MeSH-major] Carcinoma / surgery. Thymus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Care / methods. Preoperative Care / methods. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15296905.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Miyazawa M, Yamanda T, Kaneko K, Yoshida K, Machida E, Hanaoka T, Takasuna K, Kondo R, Numanami H, Makiuchi A, Haniuda M, Amano J: [Clinical study of operated nine thymic carcinomas]. Kyobu Geka; 2001 Feb;54(2):89-93; discussion 93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of operated nine thymic carcinomas].
  • Nine cases of thymic carcinoma (5 males and 4 females) were operated in our hospital between 1990 and 1998.
  • These cases included 4 squamous cell carcinomas, 2 small cell carcinomas, 2 undifferentiated carcinomas and one adenocarcinoma.
  • Preoperative chemotherapy were performed in 3 cases.
  • Adjuvant chemotherapy were administered in 4 cases and re-operation were performed in 2 cases.
  • Within 2 years after operation, 3 cases (two complete resection cases and one exploratory thoracotomy case) were died of the carcinoma.
  • However, two cases of squamous cell carcinoma have been alive more than 5 years after surgery followed by chemoradiation.
  • The remaining 4 patients are alive either with or without the carcinoma after 7 to 28 months after operation.
  • Thymic carcinoma is not so common mediastinal tumor but is expected to increase in the future.
  • The treatment of thymic carcinoma remains a controversial matter and the survival is poor compared with invasive thymoma, but multimodal-therapy would contribute to improvement of the results in treatment for thymic carcinoma especially in squamous cell carcinoma.
  • [MeSH-major] Carcinoma / surgery. Thymus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11211776.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Takemura Y, Yuba T, Kono K, Hosogi K, Osugi S, Kuwahara H, Nagata K, Harada H, Yokomura I, Iwasaki Y: [Six cases of thymic carcinoma: a clinical review]. Nihon Kokyuki Gakkai Zasshi; 2004 Jul;42(7):660-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Six cases of thymic carcinoma: a clinical review].
  • Thymic carcinoma is rarer than thymoma and carries a very poor prognosis.
  • No standard treatment has yet been established.
  • Chemotherapy and radiation therapy are usually given to patients in whom surgery is not indicated.
  • We clinically review six patients with thymic carcinoma (three men and three women) who were admitted to our hospital from 1992 through 2002.
  • Histologically, five cases were squamous cell carcinomas, and one was a lymphoepithelioma-like carcinoma.
  • Only one patient was able to undergo surgery, two received radiation therapy alone, and three were administered chemoradiation.
  • The response to radiation therapy was partial response in one patient and no change in one.
  • In summary, chest pain is the most common symptom of thymic carcinoma.
  • A symptomatic case suggests a poor prognosis resulting from the clinical behavior of thymic carcinoma, such as early distant metastasis or direct invasion of surrounding organs.
  • Histologically, squamous cell carcinoma is the most common, and thymic carcinoma appears to be generally resistant to chemotherapy and radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Thymoma / therapy. Thymus Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15357270.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Nonaka T, Tamaki Y, Higuchi K, Katoh H, Nakahashi M, Horikoshi H, Takahashi K, Minato K, Sugihara S, Kojima M: The role of radiotherapy for thymic carcinoma. Jpn J Clin Oncol; 2004 Dec;34(12):722-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of radiotherapy for thymic carcinoma.
  • OBJECTIVE: The aim of this study is to evaluate retrospectively the role of radiotherapy for thymic carcinoma.
  • METHODS: Between 1973 and 1998, 14 patients with thymic carcinoma were treated at Gunma Prefectural Cancer Center.
  • The pathological subtype according to the World Health Organization histological criteria for thymic tumors was squamous cell carcinoma (low-grade histology) in six cases and undifferentiated carcinoma (high-grade histology) in six.
  • Ten patients (83%) received radiotherapy as a curative intent, and the median dose was 60 Gy.
  • Systemic chemotherapy was administered to four patients (33%), and the majority (75%) of the regimens contained cisplatin.
  • Histological subtype (low-grade versus high-grade), surgical resection (complete versus incomplete), radiotherapy and chemotherapy were evaluated as prognostic factors in a univariate analysis.
  • Radiotherapy plays an important role in treating thymic carcinoma in terms of reducing local recurrence and prolonging survival time.
  • Establishment of an innovative treatment protocol that includes chemotherapy is necessary to control intrathoracic relapse and distant metastasis.
  • [MeSH-major] Carcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Thoracotomy. Thymus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15640502.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


32. Takeda S, Hirano H, Maeda H, Sawabata N, Okumura Y, Asada H: Thymic carcinoma with a large cystic lesion. Jpn J Thorac Cardiovasc Surg; 2004 Dec;52(12):574-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic carcinoma with a large cystic lesion.
  • A computed tomography (CT) and magnetic resonance imaging showed a well-circumscribed cystic mass, 12 cm in size adjacent to the heart border and superior vena cava (SVC).
  • A CT guided needle biopsy was performed, and instead of detecting malignant tissues but finding that gray muddy fluid was suctioned, suggesting cystic teratoma.
  • At surgery, the tumor was confirmed advanced thymic carcinoma with pleural dissemination, then the tumor was extirpated with resection of SVC, followed by 2 cycles of chemotherapy.
  • We herein present a diagnostic pitfall case of thymic carcinoma having a large cystic component with which rare association should be recognized.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Cysts / surgery. Mediastinal Cyst / diagnosis. Thymus Neoplasms / surgery
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed. Vena Cava, Superior / surgery

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15651404.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Takahashi K, Yoshida J, Nishimura M, Nagai K: Thymic carcinoma. Outcome of treatment including surgical resection. Jpn J Thorac Cardiovasc Surg; 2000 Aug;48(8):494-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic carcinoma. Outcome of treatment including surgical resection.
  • OBJECTIVE: Thymic carcinoma is treated by the same guidelines used for thymoma, despite having a more aggressive histologic appearance and clinical course.
  • METHOD: To evaluate the outcome of treatment, patients undergoing treatment including surgery at the National Cancer Center Hospital East were reviewed and reported with descriptions of postoperative pathologic stages based on Masaoka staging.
  • RESULTS: Six Japanese patients--2 men and 4 women with a median age of 59 years (range: 23-67)--underwent treatment, including surgery.
  • The histologic type of tumor was squamous cell carcinoma in 4, 1 of which was associated with invasive thymoma; adenosquamous carcinoma associated with thymoma in 1; and lymphoepithelioma-like carcinoma in 1.
  • Four of the 6 patients survived--2 stage II were alive and well with no evidence of disease 69 months and 44 months after surgery; 1 stage III was alive with the disease 44 months after preoperative chemotherapy and subsequent surgery; and 1 stage III was alive with multiple pulmonary metastases 17 months after surgery.
  • A stage IVa died of the tumor 48 months after preoperative chemotherapy and subsequent surgery, while 1 stage III died of the tumor 35 months after surgery.
  • CONCLUSION: The outcome of thymic carcinoma treatment must be reported using the same histologic typing and staging.
  • Further study is warranted to define precise treatment strategy for this disease.
  • [MeSH-major] Carcinoma / therapy. Thymus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Female. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11002578.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down






Advertisement